HIV-associated TB mortality and blocks in the cascade

Slides:



Advertisements
Similar presentations
HIV TB. World wide TB is the most common cause of death in people with HIV About 1/3 of HIV infected people worldwide are co-infected with TB (co-infection.
Advertisements

Excellent healthcare – locally delivered Strengthening the treatment cascade Evidence and practice Dr Nathan Ford Treatment and Care Department of HIV.
The South African Cryptococcal Screening Program: Program update XIX international AIDS Conference Washington United States 24 th July 2012 Dr. Samuel.
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
Scaling up Prevention of Mother to Child Transmission of HIV (PMTCT): What Will it Take to Eliminate MTCT? Jessica Rodrigues Presentation for UNICEF Written.
80 (7.3%) patients who were initially admitted to either a general bay or to the TB cohorting bay AND were eventually transferred to the other one during.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Implications for Countries: Critical Issues in Service Delivery and Decision Making Dr. Yogan Pillay Deputy.
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
Standard of Care for MDR-TB
Reduced treatment delays for drug-resistant TB/HIV co-infected patients with decentralised care and rapid Xpert MTB/Rif test in Khayelitsha, South Africa.
Matthew Fox Center for Global Health & Development Department of Epidemiology Boston University July 17, 2011 The first step is admitting you have a problem.
Cascade of HIV Care in the Netherlands from 2002 to Esther Engelhard 14th European AIDS Conference October 18, 2013 Disclosed no conflict of interest.
Autopsies in HIV: still finding missed diagnoses after 20 years Background Mortality has significantly fallen with the advent of HAART and chemoprophylaxis.
A decentralized model of care for drug-resistant tuberculosis in a high HIV prevalence setting Cheryl McDermid, Helen Cox, Simiso Sokhela, Gilles van Cutsem,
Challenges of service integration: the TB model Linda-Gail Bekker The Desmond Tutu HIV Centre, Faculty of Health Sciences, University of Cape Town, South.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
Late Presentation of HIV Infection James Hand Clinical Nurse Manager for HIV & Hepatitis Research Barts Health NHS Trust.
Smear negative TB and HIV: urgent research priorities to inform a rolling global policy Haileyesus Getahun, MD, MPH, PhD Stop TB Department WHO/HQ.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
HIV disease in BULAWAYO Photo: WHO 2007 Dr. Paco Trinchán Medical Officer BCC August 2013.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The United Kingdom provides excellent access and quality of.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Risk of death among those awaiting treatment for HIV infection in Zimbabwe: adolescents are at particular risk ZIMA CONGRESS AUGUST 2015 VICTORIA.
The case for HIV testing A presentation for the clinical team in your practice.
Integration of TB and HIV Screening, Care and Treatment in Mulago Hospital, Uganda Rhoda Wanyenze, Doris Mwesigire, Henry Luzze, Violet Gwokyalya, Julius.
Tuberculosis as a cause of death in HIV + patients in Africa: autopsy Autopsies on 108 HIV+ patients in Botswana (selected) Cause of death: Tuberculosis37%
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER ART Initiation in Resource-Limited Settings Susan M. Graham Assistant Professor, Medicine and Global.
HIV and STI Department The case for HIV testing A presentation for the clinical team in your practice.
A Call to Action Children – The missing face of AIDS.
Innovative Strategies for Addressing Hepatitis C in Indian Country March 14, 2016.
ICASA |1 | LEARNING FROM “B+” IMPLICATIONS FOR IMPLEMENTING “TREAT ALL” Dr. Gottfried Hirnschall WHO, Geneva ICASA Harare, December 2015.
TB infection control in the era of MDR and XDR TB Haileyesus Getahun Stop TB Department WHO/HQ.
The Changing Face of Advanced Disease
TB-HIV Last updated: January 2017.
Factors associated with loss to follow up in a primary healthcare clinic practicing test and treat Authors: Julius Kiwanuka1,2, Noah Kiwanuka3, Flavia.
Amir Shroufi Medical Coordinator MSF South Africa
How differentiated care supports “Tx all” and Dr
I have no conflicts of interest to declare
Pregnancy and living with HIV
3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.
Earlier treatment and lower mortality in infants Initiating ART at
Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.
World Health Organization
Overview of Global HIV Epidemic
Addressing the challenges and successes of expediting TB treatment among PLHIV who are seriously ill: experience from Kenya Masini E & Olwande C National.
Participants 18year old+
Nazir Ismail CTB/NICD & WHO-SRL & UP
Progress in Implementing collaborative TB/HIV activities
advanced HIV disease and associated mortality : how can we do better
Meningitis Surveillance and investigation of causes of altered mental status among Kamuzu Central Hospital admissions, Lilongwe, Malawi Charles Kyriakos.
What is AIDS? HIV is a virus that attacks the immune system. If untreated, a person’s immune system will eventually be completely destroyed. AIDS refers.
TB-HIV Last updated: March 2018.
The use of cotrimoxazole prophylaxis in the context of HIV infection
HIV/AIDS Patient with a “Neuro” presentation. Diagnostic Approach
Evidence for use of urinary LAM
11/23/2018 National University of Lesotho, Southern Africa
TB-HIV Last updated: November 2018.
Advanced HIV: a WHO perspective
Knowing your epidemic and knowing your response – maximising routinely collected data to measure and monitor HIV epidemics in sub-Saharan Africa Monitoring.
Projected new adult infections and total adult deaths in sub-Saharan Africa, in millions, by the year 2020: Impact of three scenarios compared to baseline.
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Advanced HIV diagnoses among gay and bisexual men in Australia Phillip Keen, Handan Wand, Hamish McManus, Muhammad Jamil, Skye McGregor, James.
James E Scriven, David G Lalloo, Graeme Meintjes 
Management and Development for Health (MDH)
When to START During an OI
VACS Mental Health WG Joseph L. Goulet, PhD, MS Director
Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study  Sabin Nsanzimana, MD, Eric Remera, MSc, Steve Kanters,
TB Screening and Differentiated Service Delivery: State of the Art
Andreas D. Haas, PhD Postdoctoral fellow, ICAP at Columbia University
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

HIV-associated TB mortality and blocks in the cascade Dr Nathan Ford, MPH, PHD, FRCPE Dept HIV & Global Hepatitis Programme World Health Organization

Late presentation: a persistent challenge World Health Organization 15 September 2018 Late presentation: a persistent challenge CD4 at start of ART Advanced disease at enrolment (CD4 <350) 306 CD4 among people starting ART is rising, but still remains low overall, with many people still starting ART at CD4 less than 200. There are also many losses between diagnosis and start of ART. 167 IeDEA-WHO Collaboration 2015

TB is the leading cause of hospitalization 30% diagnosed with HIV at time of admission Median CD4: 131 No change over time Ford et al, JIAS 2016

Ford et al Lancet HIV 2015

Gupta et al, AIDS 2015

TB was a cause of 5% - 44% early mortality in Sub-Saharan Africa Early mortality rates are highest at Sub-Sharan Africa at 17& Most common causes of death reported were TB accounting for 5%–44% of deaths

Advanced disease ≠ late presenters N= 609 HIV-positive admissions ART status : naïve: 35.7% current:45.0% interrupted :19.3% Most frequent primary clinical diagnoses: TB ( 33.5%) Other bacterial infection (17.1%) Other AIDS-defining illnesses ( 10.9%) By 90 days follow-up, 29.9% required readmission and 13.3% died Commonest causes of death: TB (37.2%) Meintjes G et al Medicine 2015 (Slide courtesy of Eric Goemaere)

Case fatality during TB treatment by HIV status (2013 cohort) 11% 3.5% WHO Global Tuberculosis Report, 2015

No significant difference in death and default rates between HIV-positive TB patients on ART and HIV negative TB patients Died ART vs No ART = aOR 7.4 Nglazi et al, BMC ID 2015

Cascade of diagnosis and treatment of HIV in TB cases, 2013 48% 67% Lessells RJ, Swaminathan S, Godfrey-Faussett P. Current Opinions 2015

World Health Organization Acknowledgements 15 September 2018 Annabel Baddeley Meg Doherty Haileyesus Getahun Eric Goemaere CD4 among people starting ART is rising, but still remains low overall, with many people still starting ART at CD4 less than 200. There are also many losses between diagnosis and start of ART.